Dengue Vaccine Market:

The dengue vaccine market estimated to be valued at US$ 235 Mn in 2017 and poised to grow at CAGR 27.7%. The market for dengue vaccines projected to reach US$ 1,020 Mn by 2023 due to newer product launches and the dearth of treatment options.

Increase in Burden of Dengue Fever in Tropical and Subtropical Regions

Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by Aedes aegyptimosquito. Dengue fever is epidemic in several countries of Asia-pacific and Latin America region. The growing global epidemic of dengue in aforementioned regions is expected to create demand for the dengue vaccine over the forecast period. Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for dengue vaccine over the forecast period. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programmes to prevent the dengue epidemics. According to WHO estimates, there are around 50 Mn dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.

Promising Vaccine Pipeline

Currently, dengvaxia is the only vaccine available for dengue prevention in the market. Dengvaxia (CYD-TDV) is a recombinant tetravalent vaccine administered in three doses in series of 0/3/6 month schedule. However, there are around five dengue vaccine candidates are under development, which are showing positive results in different clinical trial phases. Moreover, vaccines like DENVax from Takeda Pharmaceutical Company Limited is showing better clinical benefits in all age groups and have convenient dosing pattern i.e. two doses (three months apart). Developing clinically efficacious vaccines in flexible dosing regimens expected to fuel the dengue vaccine market revenue growth over the forecast period.

Asia-Pacific Region Expected To Emerge As Leading Market for Dengue Vaccine

Asia-Pacific region expected to lead the global dengue vaccines market owing to widespread prevalence and incidence of dengue fever and large population, who are at dengue fever risk. Latin America expected to register highest market growth among all regions owing to the early adoption of the vaccine in government immunization programmes.

Competition Assessment

Key players profiled in the global dengue vaccine market include:

Sanofi (France)

Takeda Pharmaceutical Company Limited (Japan)

Insitituto Butantan(Brazil)

Vabiotech (Vietnam)

Panacea Biotech(India)

Biological E (India)

GlaxoSmithKline plc (U.K)

Merck & Co. Inc. (U.S.)

Market players are focusing on developing live and killed vaccines with improved safety and efficacy to garner larger revenue share in global dengue vaccine market.

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

About PBIGroup:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.